• Français
• Site Map
• Glossary
• Contact Us
• Home

• About DiagnoCure
  • Mission and History
  • Board of Directors
  • Management
  • Advisory Board
  • Intellectual Property
• Investors
  • Overview
  • Q&A
  • Financial Information
  • Press Releases
  • Strategy
  • Management
  • Presentations
  • Analysts
  • Corporate Governance
  • Investors Contact
• News and Events
  • Overview
  • Press Releases
  • Events
  • News Alerts
  • Media Room
• Products and Projects
  • Overview
  • Highlights on Cancer
  • Molecular Diagnostics
  • Prostate Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Bladder Cancer
  • Other R&D Projects
  • Useful Links
• Customer Service
• Career
  • A Career of Passion
  • Talent Wanted

Bladder Cancer Diagnosis with ImmunoCyt™ / uCyt+™

Diagnocure entered into a product divestment agreement for ImmunoCyt™/uCyt+™ with U.S.-based Scimedx Corporation.

More on Scimedx